Cingulate Inc (NQ: CING )
9.690
-1.650
(-14.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
All News about Cingulate Inc
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_4254.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pexels-photo-8378728.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3316.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3192.jpeg?width=720)
![](https://cdn.benzinga.com/files/images/story/2012/aapharma_3417.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_400.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_2444.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_1484.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_377.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_1335.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_105.jpg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/analyst_ratings_image_1984.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_369.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_97.jpg)
![](https://cdn.benzinga.com/files/imagecache/story_image_685x375C/images/story/2012/biotech4_1.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_356.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech_5.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_349.png)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/19916.png?v=0)
Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)
December 10, 2021
From Aegis Capital Corp.
Via AccessWire
Topics
Retirement
Exposures
Pension
![](https://investorplace.com/wp-content/uploads/2019/07/wall-street-sign-buildings.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_346.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech_3.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech2_1.jpg)
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
Via Benzinga
Exposures
Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.